摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

triphenyl(propyl)-λ5-phosphane

中文名称
——
中文别名
——
英文名称
triphenyl(propyl)-λ5-phosphane
英文别名
——
triphenyl(propyl)-λ5-phosphane化学式
CAS
——
化学式
C21H23P
mdl
——
分子量
306.4
InChiKey
OFRQDOWTZJNPHH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

文献信息

  • [EN] HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES COMME INHIBITEURS DE LA BÊTA-LACTAMASE
    申请人:ASTRAZENECA AB
    公开号:WO2013150296A1
    公开(公告)日:2013-10-10
    The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R 2, R 3 and R 4 are described herein.
    本发明涉及一种β-内酰胺酶抑制剂化合物。这些化合物及其药学上可接受的盐,可与β-内酰胺类抗生素结合使用,或单独使用,用于治疗细菌感染,包括由耐药菌株引起的感染,包括多药耐药菌株引起的感染。本发明包括根据式(Ia)的化合物:或其药学上可接受的盐,其中R1、R2、R3和R4的值如本文所述。
  • [EN] SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS<br/>[FR] COMPOSÉS AROMATIQUES SUBSTITUÉS ET COMPOSITIONS PHARMACEUTIQUES POUR LA PRÉVENTION ET LE TRAITEMENT DE L'OSTÉOPOROSE
    申请人:PROMETIC BIOSCIENCES INC
    公开号:WO2016054728A1
    公开(公告)日:2016-04-14
    The present invention concerns the use of compounds for preventing and/or treating osteoporosis, for stimulating bone formation, for stimulating bone remodeling, for stimulating the differentiation and mineralization of osteoblasts, for inhibiting bone resorption and for modulating serum level of adiponectin in a subject. These uses have been found for compounds represented by Formula I and pharmaceutically acceptable salts thereof. wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)-(CH2)n-CH3 or CH(OH)-(CH2)n-CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is H, F, OH, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)-(CH2)n-CH3 or CH(OH)-(CH2)n-CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F, or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(F)-C(O)OH, 3) CF2-C(O)OH or 4) C(O)-C(O)OH.
    本发明涉及用于预防或治疗骨质疏松症、刺激骨骼形成、刺激骨骼重塑、刺激成骨细胞的分化和矿化、抑制骨吸收以及调节受试者血清中脂联素平的化合物的用途。已经发现,这些用途适用于由公式I表示的化合物及其药用可接受的盐。其中A是C5烷基、C6烷基、C5烯基、C6烯基、C(O)-(CH2)n-CH3或CH(OH)-( )n- ,其中n是3或4;R1是H、F或OH;R2是H、F、OH、C6烷基、C5烯基、C6烯基、C(O)-( )n- 或CH(OH)-( )n- ,其中n是3或4;R3是H、F、OH或 Ph;R4是H、F或OH;Q是1) ( )mC(O)OH,其中m是1或2,2) CH(F)-C(O)OH,3) CF2-C(O)OH或4) C(O)-C(O)OH。
  • HETEROARYL-PYRAZOLE DERIVATIVE
    申请人:Nakamura Toshio
    公开号:US20130137865A1
    公开(公告)日:2013-05-30
    A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.
    公式[I]所代表的化合物及其药学上可接受的盐是一种新颖的化合物及其药学上可接受的盐,对II类代谢型谷酸(mGlu)受体具有拮抗活性,并且作为一种新型预防或治疗剂对情绪障碍(抑郁症、双相情感障碍等)、焦虑障碍(广泛性焦虑障碍、恐慌障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧障碍、急性应激障碍等)、精神分裂症、阿尔茨海默病、认知障碍、痴呆、药物依赖、抽搐、颤抖、疼痛、睡眠障碍等疾病具有有效性。
  • [EN] FLUORESCENT RHODAMINE DYES WITH ENHANCED CELL PERMEABILITY<br/>[FR] COLORANTS FLUORESCENTS À BASE DE RHODAMINE À PERMÉABILITÉ CELLULAIRE AMÉLIORÉE
    申请人:MAX PLANCK GESELLSCHAFT
    公开号:WO2021160732A1
    公开(公告)日:2021-08-19
    The invention relates to novel fluorescent rhodamine dyes with enhanced cell permeability which are rhodamine 4´-isomers having the following general structural formula A: wherein Z is selected from O(alkyl), O(aryl), S(aryl), S(O)(alkyl), S(O)(aryl), S(O)2(alkyl), S(O)2(aryl), S(O)2(-O-alkyl), S(O)2(-O-aryl), S(O)2NH(alkyl), S(O)2NH(aryl), S(O)2N(alkyl)2, S(O)2N(aryl)2, S(O)2N(alkyl)(aryl), C(O)O(alkyl), C(O)O(aryl), C(O)(alkyl), C(O)(aryl), P(O)OH(-NH-alkyl), P(O)OH(-O-alkyl), P(O)OH(-NH-aryl), P(O)OH(-O- aryl), P(O)(-O-alkyl)2, P(O)(-NH-alkyl)2, P(O)OH(-N(alkyl)2), P(O)OH(-N(aryl)2), P(O)(-N(aryl)2)2, P(O) (-N(alkyl)2)(-N(alkyl)2), P(O)(-O-aryl)2, P(O)(-NH-aryl)2, P(O)(-O-alkyl)(-O-aryl), P(O)(-NH-alkyl)(-O-aryl), P(O)(- O-alkyl)(-NH-aryl), P(O)(-NH-alkyl)(-NH-aryl), C(O)OH, C(O)NH(alkyl), C(O)NH(aryl), CON(alkyl)2, CON(aryl)2, in particular C(O)OH, C(O)NH(alkyl), C(O)NH(aryl), CON(alkyl)2, CON(aryl)2, C(O)O(alkyl) and C(O)O(aryl), or any group which is neither Cl, NH2 or NO2 and which induces a neighboring group effect via steric, ionic or bonding interactions with the adjacent carboxyl group resulting in a shift of the equilibrium between zwitterionic form and spirolactone form towards the spirolactone form. The invention further relates to 4´-isomer derivatives and probes comprising such 4´-isomers coupled to at least one reactive group or ligand which is capable to interact with or bind to other molecules, wherein said reactive group or ligand may be coupled to the rhodamine 4´-isomer fluorophore either directly or via a linker. Another aspect of the invention relates to the use of these compounds and conjugates as labels in microscopic, spectroscopic and other imaging techniques and/or as cell permeable substances penetrating through membranes of living and fixed cells in vivo or in vitro.
    该发明涉及具有增强细胞渗透性的新型荧光罗丹明染料,其为具有以下一般结构式A的罗丹明4´-异构体:其中Z从O(烷基)、O(芳基)、S(芳基)、S(O)(烷基)、S(O)(芳基)、S(O)2(烷基)、S(O)2(芳基)、S(O)2(-O-烷基)、S(O)2(-O-芳基)、S(O)2NH(烷基)、S(O)2NH(芳基)、S(O)2N(烷基)2、S(O)2N(芳基)2、S(O)2N(烷基)(芳基)、C(O)O(烷基)、C(O)O(芳基)、C(O)(烷基)、C(O)(芳基)、P(O)OH(-NH-烷基)、P(O)OH(-O-烷基)、P(O)OH(-NH-芳基)、P(O)OH(-O-芳基)、P(O)(-O-烷基)2、P(O)(-NH-烷基)2、P(O)OH(-N(烷基)2)、P(O)OH(-N(芳基)2)、P(O)(-N(芳基)2)2、P(O)(-N(烷基)2)(-N(烷基)2)、P(O)(-O-芳基)2、P(O)(-NH-芳基)2、P(O)(-O-烷基)(-O-芳基)、P(O)(-NH-烷基)(-O-芳基)、P(O)(-O-烷基)(-NH-芳基)、P(O)(-NH-烷基)(-NH-芳基)、C(O)OH、C(O)NH(烷基)、C(O)NH(芳基)、CON(烷基)2、CON(芳基)2,特别是C(O)OH、C(O)NH(烷基)、C(O)NH(芳基)、CON(烷基)2、CON(芳基)2、C(O)O(烷基)和C(O)O(芳基),或者任何既非Cl、NH2或NO2又通过立体、离子或键合相互作用与相邻羧基引起邻基效应的基团,导致席洛内酮形式和螺内酯形式之间的平衡向螺内酯形式的转变。该发明还涉及4´-异构体衍生物和探针,其包括将这种4´-异构体偶联到至少一个能够与其他分子相互作用或结合的反应性基团或配体,其中所述反应性基团或配体可以直接或通过连接剂偶联到罗丹明4´-异构体荧光团。该发明的另一个方面涉及将这些化合物和结合物用作显微镜、光谱和其他成像技术中的标记,和/或作为穿透活体或体外固定细胞膜的细胞渗透性物质。
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    申请人:Constellation Pharmaceuticals, Inc.
    公开号:US20150315148A1
    公开(公告)日:2015-11-05
    Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    这里提供了用于调节甲基修饰酶的药剂、组合物及其用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫